Treat-to-Target Strategy Cuts Mortality in Gout Patients Save
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
"Failure to reach a target serum uric acid (sUA) level of 6 mg/dL is an independent predictor of mortality in gout patients. Control of gout with achievement of sUA target less than 6 mg/dL should be considered in order to improve patient survival," said Fernando Perez-Ruiz, MD, PhD, a rheumatologist at Hospital Universitario Cruces in Baracaldo, Spain.
In 2014, a group of European researchers found a series of variables were linked in gout patients to higher mortality risk, including serum urate levels at baseline and during therapy, flares, and comorbidities.
Perez-Ruiz said of the first study of 700 patients, "Severity of gout was associated with increased risk of mortality, but we could not find a signal for serum urate while on treatment."
He said a prospective, follow-up cohort study was conducted in 1,193 patients treated at a gout clinic from 1992 to 2017. Eighty-five percent of these patients had gout confirmed with either microscope or ultrasound scan. They had at least one follow-up visit.
Researchers confirmed mortality from medical records, patients' families, or local death registries. Patients' serum uric acid levels were monitored during follow-up, and the study used the average serum uric acid level until stabilization as the primary exposure, defined as less than 6 mg/dL versus more than 6 mg/dL.
Perez-Ruiz said lowering serum uric acid levels to a target of less than 6 mg/dL reduced mortality risk in individuals with gout.
The mean serum uric acid level at baseline was 9.1 mg/dL, and 16.3 percent of patients maintained serum uric acid levels of 6 or more mg/dL despite treatment.
A total of 158 deaths occurred among participants in the study, for rates of 13% overall and 32.7 per 1,000 patient-years.
Mortality was significantly higher for patients whose serum uric acid level was over 6 mg/dL (80.9 per 1,000 person-years).
After adjusting for age, sex, previous cardiovascular events, and baseline serum uric acid concentration, a serum uric acid level of 6 mg/dL or higher was associated with higher mortality risk, with a hazard ratio of 2.39.
The approach to managing hyperuricemia in gout often is based on treating flares unless severe gout develops, noted Perez-Ruiz. But he added the new research supports a treat-to-target intervention to reach therapeutic serum urate levels.
"This new analysis shows that although a signal for developing severe gout remains, reaching serum urate therapeutic target is associated with lower mortality risk than being over target," he said. "Although we cannot exclude other variables not included in our database, such as control of comorbid conditions, our results encourage making any clinically acceptable effort to reach and maintain serum urate levels on target."
Perez-Ruiz said rheumatologists ought not take a position of "two flares a year, that's not bad."
He said treatment ought to take a treat-to-target approach similar to reducing high cholesterol levels to avoid myocardial infarctions.
Shraddha Jatwani, MD, press conference moderator and an adult rheumatologist at St. Vincent Hospital in Evansville, Indiana, said the findings from the Spanish study should motivate community rheumatologists to persuade non-compliant patients to take their medications to help reduce mortality. She said many gout patients don't see the need for taking daily medications when their gout pain lets up.